Biocode Technologies researches, incubates and commercialises inflammation-centred medical technologies. They concentrate specifically on diagnostic solutions that contribute to the management and improvement of human health and wellbeing. Their expanding brand family currently comprises Biocheck, which focuses on rapid testing, and Biolab, which focuses on diagnostic methodologies.

CapeBio Technologies intends to develop a state-of-the-art AI platform to mine metagenomic data for novel antimicrobial peptide genes. This is a machine-learning and data-science-driven application that allows for better and novel detection of medically important genes that can be used to fight diseases such as cancer and tuberculosis.